GA-101, a third-generation, humanized and glyco-engineered anti-CD20 mAb for the treatment of B-cell lymphoid malignancies.
Year: 2009
Type: article
Source: PubMed
Author: Tadeusz Robak
Institutions: Copernicus Memorial Hospital, Medical University of Lodz
Language: English
Subfield: Pathology and Forensic Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W1852939045
